ArticleEuropean journal of nuclear medicine and molecular imaging2026
Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer.
Angelique Loor et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.